

| Report Number: | 22-014012/D004.R001 |
|-----------------|---------------------|
| Report Date: | 11/23/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 11/15/22 12:43 |

This is an amended version of report# 22-014012/D004.R000.

| Customer: | ATL Rx |
|-------------------|--------------------|
| Product identity: | Live D8- Lava Kush |
| Client/Metrc ID: | |
| Laboratory ID: | 22-014012-0002 |

| Potency: | I | | 1 | |
|-----------------|------------|-------------------------------------|-----------------|------------------------|
| Analyte | Result (%) | | | 2.040/ |
| $\Delta 8$ -THC | 68.9 | | CBD-Total | 3.84% |
| CBD-A | 4.25 | 8-THC | | |
| ∆8-THCV | 0.204 | CBD-A | THC-Total | 0.170% |
| THC-A | 0.194 | 8-THCV | | |
| СВТ | 0.181 | THC-ACBT | (Reported in pe | rcent of total sample) |
| CBG-A | 0.120 | CBT CBG-A | | |
| CBD | 0.113 | • CBD | | |
| | | 000 | | |
| | | | | |

 Www.columbialaboratories.com
 Page 1 of 8

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430





| Report Number: | 22-014012/D004.R001 |
|-----------------|---------------------|
| Report Date: | 11/23/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 11/15/22 12:43 |

Customer:

ATL Rx

| Product identity: | Live D8- Lava Kush |
|----------------------|--------------------|
| Client/Metrc ID: | |
| Sample Date: | |
| Laboratory ID: | 22-014012-0002 |
| Evidence of Cooling: | No |
| Temp: | 9.6 |
| Relinquished by: | hinton |

Sample Results

| Potency | Method: J AOAC 20 | 15 V98-6 (mod) | Units % | Batch: 2209904 | Analyze: 11/16/22 | 9:47:00 PM |
|--------------------|-------------------|----------------------------|---------|----------------|-------------------|------------|
| Analyte | As Dry | | otes | | | |
| | Received weight | ght | | | | |
| CBC | < LOQ | 0.0725 | | | | 8-THC |
| CBC-A | < LOQ | 0.0725 | | | | CBD-A |
| CBC-Total | < LOQ | 0.136 | | | | 8-THCV |
| CBD | 0.113 | 0.0725 | | 1 | | THC-A |
| CBD-A | 4.25 | 0.0725 | | | | CBT |
| CBD-Total | 3.84 | 0.136 | | | | CBG-A |
| CBDV | < LOQ | 0.0725 | | | | CBD |
| CBDV-A | < LOQ | 0.0725 | | | | |
| CBDV-Total | < LOQ | 0.135 | | | | |
| CBE | < LOQ | 0.0725 | | | | |
| CBG | < LOQ | 0.0725 | | | | |
| CBG-A | 0.120 | 0.0725 | | | | |
| CBG-Total | < LOQ | 0.135 | | | | |
| CBL | < LOQ | 0.0725 | | | | |
| CBL-A | < LOQ | 0.0725 | | | | |
| CBL-Total | < LOQ | 0.136 | | | | |
| CBN | < LOQ | 0.0725 | | | | |
| CBT | 0.181 | 0.0725 | | | | |
| $\Delta 10$ -THC | < LOQ | 0.0725 | | | | |
| $\Delta 8$ -THC | 68.9 | 0.725 | | | | |
| $\Delta 8$ -THCV | 0.204 | 0.0725 | | | | |
| ∆9-THC | < LOQ | 0.0725 | | | | |
| exo-THC | < LOQ | 0.0725 | | | | |
| THC-A | 0.194 | 0.0725 | | | | |
| THC-Total | 0.170 | 0.136 | | | | |
| THCV | < LOQ | 0.0725 | | | | |
| THCV-A | < LOQ | 0.0725 | | | | |
| THCV-Total | < LOQ | 0.135 | | | | |
| Total Cannabinoids | 74.0 | | | | | |

Page 2 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





Report Number: 22-014012/D004.R001 Report Date: 11/23/2022 **ORELAP#:** OR100028 Purchase Order: Received: 11/15/22 12:43

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

^b = ISO/IEC 17025:2017 accredited method.

Units of Measure

% = Percentage of sample

% wt = $\mu g/g$ divided by 10,000

Approved Signatory

Derrick Tanner General Manager

www.columbialaboratories.com

Page 3 of 8

Test results relate only to the parameters tested and to the samples as received by equirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made

| Columbia LABORATORIES A Tentamus Company | | 12423 NE Whitaker Way Portland, OR 97230 503-254-1794 | | | | | | | | Re Ol Pu | eport Number: eport Date: RELAP#: urchase Order: eceived: | 22-014012/D004.R00 11/23/2022 OR100028 11/15/22 12:43 | 01 |
|---|----------------------|---|-------------------|------------|-----------------|--------|-----|----------|----------------------------------|---------------------|---|--|----|
| Columbia LAGORATORIES CAteristic Greey | Hemp & | Ch | ain o | F Cust | Extrac ody R | ecord | | ed Produ | | | | :5 22 | |
| Company: IHC LLC | | | an Hea | | Analysis | Reques | ted | | | Numbe roject l | | | |
| Contact: Kyle Farook | | ni | abi vy oid Mel | ticid | | | | | Batch ID: | | D: | | |
| Address: 431 NW Flanders st. City: Portland Str | ate: OR Zip Code: 97 | | als | es | | | | | Sampled by: Custom Reporting: | | | | |
| City: Onland Sta ☑ Email Results: kyle@thehempcollect. | | Pote ncy | | | | | | | | | | | |
| □ Ph: (610) - 6081643 Billing Contact (if | | | ., | | | | | | Reportin | ng Type | : ☑ - Ind. Hemp product □ - Rec. Ca : □ - Compliance ☑ - R&D ÆTRC □ - ODA □ - USDA ther: | nnabis | |
| Address: | | | | | | | | | | Turi | around time (TAT - Business Days): | | |
| City: | State:Zip: | | | | | | | | | - | - 5BD - 3BD* - 2BD* *Check for availability | | |
| Ph: () | | Sample | | | | | | | Material | Neight | | | |
| Lab ID Client Sample Ident | ification | date | | | | - | | | Type † | (Units) | Comments/Metrc ID | | |
| Live D8 DT - Garlie Jam | | 11/15 11/15 | - | | | - | | | | | Samples #1-#4 : Alternate Client na ATLrx | me: | |
| 00 | | 11/15 | | | | + | | | | | | | |
| O3 Live D8 - Sour Pineapple | | 11/15 | | | | | | | | | 5 business day turnaround on samp 2 business day turnaround on samp | Nes 1-6, | |
| OX Sour Suver | | 11/15 | ~ ~ | ~ | | | | | | | e ooomooo day tamatoana on samp | | |
| Sour Hawaiian | | 11/15 | ~ | | | | | | | | | | |
| CBDa seed solution | | 11/15 | | | | | | | | | | | |
| | | | | | | 1 | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| Signature - Relinquished By: | Date | Time | | ure - Rece | | Dat | | Time | | | Lab Use Only: | | |
| Forest Heims | | 2:00 PM | n | M | 5 | 11 | 15 | 12:05 | Evidence | | or □ Client bling: □ Yes 🖾 No - Temp (°C):9 | drop off | |
| mreno- | 11/15 12 | 2:20 | RS | 35 | | 11/15 | ri | 1243 | Sample Payment | in good t: 🗆 Cas | condition: 🖄 Yes 🗆 No h 🗆 Check 🗆 CC 🗆 Net: | | |
| | | | | | | _ | | | Prelog st | orage: | | | |

Hotterial Type Codes: Plant Material (P) ; Isolate (i) : Concentrate/Stratet (C) ; Tincture/Topical (T) ; Edible (i) ; Beverage (ii) ; Vapor Product (V)
Sampla: submitted to Columbia Laboratories with stating requirements constitute on agreement for service an accountace with the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of anyway associated with this COC. By signing "Reinpublic by" our air agreement for the service and the concentrate of the service associated with this COC. By signing "Reinpublic by" our air agreement for the service and the service associated with this COC. By signing "Reinpublic by" our air agreement for the service associated with the concentrate associated with the

Page 4 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-014012/D004.R001 |
|-----------------|---------------------|
| Report Date: | 11/23/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 11/15/22 12:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| J AOAC 2015 V98- | .6 | | Lai | - si atol y | Quality Co | atch ID: 2 | | | |
|---|-----|---|--|-------------|-----------------------|--|---|--|-------|
| Laboratory Contro | | | | | U | attirib. 2 | 203304 | | |
| Analyte | LCS | Result | Spike | Units | % Rec | L | imits. | Evaluation | Notes |
| CBDVA | 2 | 0.105 | 0.102 | % | 102 | 80.0 | - 120 | Acceptable | 10125 |
| BDV | 2 | 0.108 | 0.106 | % | 102 | 80.0 | - 120 | Acceptable | |
| CBE | 2 | 0.108 | 0.106 | % | 102 | 80.0 | - 120 | Acceptable | |
| BDA | 1 | 0.0960 | 0.095 | % | 102 | 90.0 | - 110 | Acceptable | |
| CBGA | 1 | 0.0963 | 0.094 | % | 101 | 80.0 | - 120 | Acceptable | |
| CBG | 1 | 0.102 | 0.099 | % | 102 | 80.0 | - 120 | Acceptable | |
| CBD | 1 | 0.102 | 0.098 | % | 103 | 90.0 | - 110 | Acceptable | |
| THCV | 2 | 0.104 | 0.102 | % | 101 | 80.0 | - 120 | Acceptable | |
| 18THCV | 2 | 0.111 | 0.109 | % | 101 | 80.0 | - 120 | Acceptable | |
| THCVA | 2 | 0.102 | 0.100 | % | 102 | 80.0 | - 120 | Acceptable | |
| CBN | 1 | 0.102 | 0.102 | % | 102 | 80.0 | - 120 | Acceptable | |
| exo-THC | 2 | 0.100 | 0.098 | % | 102 | 80.0 | - 120 | Acceptable | |
| 19THC | 1 | 0.106 | 0.102 | % | 102 | 90.0 | - 110 | Acceptable | |
| 18THC | 1 | 0.105 | 0.103 | % | 102 | 90.0 | - 110 | Acceptable | |
| CBL | 2 | 0.101 | 0.100 | % | 101 | 80.0 | - 120 | Acceptable | |
| 110THC | 1 | 0.0921 | 0.090 | % | 102 | 80.0 | - 120 | Acceptable | |
| CBC | 2 | 0.108 | 0.105 | % | 103 | 80.0 | - 120 | Acceptable | |
| HCA | 1 | 0.0940 | 0.093 | % | 101 | 90.0 | - 110 | Acceptable | |
| CBCA | 2 | 0.104 | 0.103 | % | 100 | 80.0 | - 120 | Acceptable | |
| CBLA | 2 | 0.108 | 0.106 | % | 103 | 80.0 | - 120 | Acceptable | |
| CBT | 2 | 0.112 | 0.110 | % | 102 | 80.0 | - 120 | Acceptable | |
| Method Blank | | | | | | | | | |
| Analyte | | esult | LOQ | | Units | | imits. | Evaluation | Notes |
| CBDVA | | LOQ | 0.077 | | % | | 0.077 | Acceptable | |
| CBDV | | LOQ | 0.077 | | % | |).077 | Acceptable | |
| CBE | | LOQ | 0.077 | | % | < 0.077 | | Acceptable | |
| CBDA | | LOQ | 0.077 | | % | < 0.077 | | Acceptable | |
| CBGA | | LOQ | 0.077 | | % | | 0.077 | Acceptable | |
| CBG | | LOQ | 0.077 | | % | < 0.077 | | Acceptable | |
| CBD | | LOQ | 0.077 | | % | | 0.077 | Acceptable | |
| THCV | | LOQ | 0.077 | I | % | | 0.077 | Acceptable | |
| 18THCV | | LOQ | 0.077 | L | % | | 0.077 | Acceptable | |
| THCVA | | LOQ | 0.077 | | % | | 0.077 | Acceptable | |
| CDM | < | LOQ | 0.077 | | % | | 0.077 | Acceptable | |
| | | | 0.077 | | % | | 0.077 0.077 | Acceptable | |
| xo-THC | | LOQ | 0.077 | | % | | 1.0// | Acceptable | |
| exo-THC I9THC | < | LOQ | 0.077 | | | | 077 | | |
| exo-THC I9THC I8THC | < | | 0.077 | | % | < (| 0.077 | Acceptable | |
| exo-THC 19THC 18THC CBL | < | | 0.077 | | % % | < (| 0.077 | Acceptable | |
| exo-THC 19THC 18THC CBL 110THC | | LOQ LOQ LOQ LOQ | 0.077 0.077 0.077 | | % % % | < () | 0.077 | Acceptable Acceptable | |
| exo-THC J9THC J8THC CBL J10THC CBC | | | 0.077 0.077 0.077 0.077 | | % % % | < () < () < () < () | 0.077 0.077 0.077 | Acceptable Acceptable Acceptable | |
| CBN exo-THC d9THC d8THC CBL d10THC CBC THCA | | LOQ LOQ LOQ LOQ LOQ LOQ | 0.077 0.077 0.077 0.077 0.077 | | % % % % | <pre> < 0 < 0 < 0 </pre> | 0.077 0.077 0.077 0.077 | Acceptable Acceptable Acceptable Acceptable | |
| exo-THC d9THC d8THC CBL d10THC CBC FHCA CBCA | | LOQ LOQ LOQ LOQ LOQ LOQ LOQ | 0.077 0.077 0.077 0.077 0.077 0.077 | | % % % % % | < () < () < () < () < () < () | 0.077 0.077 0.077 0.077 0.077 | Acceptable Acceptable Acceptable Acceptable Acceptable | |
| exo-THC 19THC 18THC CBL 110THC CBC FHCA | | LOQ LOQ LOQ LOQ LOQ LOQ | 0.077 0.077 0.077 0.077 0.077 | | % % % % | | 0.077 0.077 0.077 0.077 | Acceptable Acceptable Acceptable Acceptable | |

ND - None Detected at or above MRL

RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure: % - Percent

Page 5 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-014012/D004.R001 |
|-----------------|---------------------|
| Report Date: | 11/23/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 11/15/22 12:43 |

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

| J AOAC 2015 V98-6 | | | | | Ba | tch ID: 2209904 | | | | | | | |
|-------------------|--|--|-------|-------|------|-----------------|------------|-------|--|--|--|--|--|
| Sample Duplicate | Sample ID: 22-013998-0001 | | | | | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | | | | | |
| CBDVA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBDV | 0.207 | 0.219 | 0.077 | % | 5.86 | < 20 | Acceptable | | | | | | |
| CBE | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBDA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBGA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBG | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBD | 85.0 | 90.3 | 0.077 | % | 6.08 | < 20 | Acceptable | | | | | | |
| THCV | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| d8THCV | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| THCVA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBN | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| exo-THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| d9THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| d8THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBL | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| d10THC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBC | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| THCA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBCA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBLA | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |
| CBT | <loq< td=""><td><loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<></td></loq<> | <loq< td=""><td>0.077</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 0.077 | % | NA | < 20 | Acceptable | | | | | | |

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

Units of Measure:

Page 6 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





| Report Number: | 22-014012/D004.R001 |
|-----------------|---------------------|
| Report Date: | 11/23/2022 |
| ORELAP#: | OR100028 |
| Purchase Order: | |
| Received: | 11/15/22 12:43 |



Page 7 of 8 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made. Testing in accordance with: OAR 333-007-0430





22-014012/D004.R001 **Report Number: Report Date:** 11/23/2022 ORELAP#: OR100028 **Purchase Order:** 11/15/22 12:43 **Received:**

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |

 www.columbialaboratories.com
 Page 8 of 8

 Test results relate only to the parameters tested and to the samples as received by the laboratory. Test results meet all requirements of NELAP and the Columbia Laboratories quality assurance plan unless otherwise noted. This report shall not be reproduced, except in full, without the written consent of this laboratory. Samples will be retained for a maximum of 30 days from the receipt date unless prior arrangements have been made.

 Testing in accordance with:
 OAR 333-007-0430